



The following formulary decisions and updates apply to **Optum Rx<sup>®</sup> standard EHB formularies**.

The Optum Rx Business Committee meets monthly to evaluate tier placements and new prescription products approved by the Food and Drug Administration (FDA). This committee makes decisions based on information and recommendations from the Optum Rx Pharmacy & Therapeutics Committee, comprised of independent physician providers and pharmacists.

The following are the strategic clinical decisions made in the past month. Your actual plan's copays and/or coinsurance may differ from those indicated depending on the selected plan design, which determines coverage and pharmacy provider(s).

The tier chart below does not necessarily correlate to Centers for Medicare and Medicaid Services (CMS) submission tiers.

HIX BASE (RxBuilder) Tiers	HIX ENHANCED (RxBuilder) Tiers
Generic = 1	Low-Cost Generic = LCG
Preferred Brand = 2	Generic = 1
Non-Preferred Brand = 3	Preferred Brand = 2
Specialty = 4	Non-Preferred Brand = 3
Both versions include preventive (PV) drugs which may have \$0 when health care reform requirements are met.	Specialty Generic & Specialty Preferred Brands = 4
Both versions may contain Oral Chemo (CM) tier if elected.	Specialty Non-Preferred Brands = 5

**Key**    **SP:** Specialty Pharmacy    **PA:** Prior Authorization    **ST:** Step Therapy    **QL:** Quantity Limits

## Optum Rx Humira and Stelara biosimilar management for Jan. 1, 2025

Continuing with our phased biosimilar approach, Optum Rx constantly negotiates with manufacturers in order to bring value to the market by driving biosimilar competition, supporting innovation and lowering overall health care costs. Our latest Humira and Stelara biosimilar management strategies will deliver savings for your plans while preserving quality and optionality for both plans and patients.

These new biosimilar strategies continue to meet our **patient-first guiding principles** while delivering a lower net cost:

- Continued quality of care for patients.
- FDA-approved interchangeability.
- Stable supply.
- Availability of formulations and drug strengths to provide continuity of care.
- Affordability for patients, including manufacturer copay assistance programs, and significant cost reduction for plan sponsors

Humira biosimilar strategy				
	CURRENT		EFFECTIVE JAN. 1, 2025	
<b>EHB Standard Formularies</b>	<b>Specialty with PA</b>	<b>Excluded</b> All other branded and unbranded biosimilars	<b>Specialty with PA</b>	<b>Excluded</b> Humira and all other branded and unbranded biosimilars
	<ul style="list-style-type: none"> <li>• Humira</li> <li>• Amjevita HW &amp; LW (Amgen)</li> <li>• Cyltezo &amp; Adalimumab-adbm</li> <li>• Hyrimoz &amp; Adalimumab-adaz</li> </ul>		<ul style="list-style-type: none"> <li>• Amjevita for Nuvaila (LW)</li> <li>• Amjevita for Amgen (HW)</li> </ul>	

Stelara biosimilar strategy		
	CURRENT	EFFECTIVE JAN. 1, 2025
<b>EHB Standard Formularies</b>	<b>Specialty with PA</b> <ul style="list-style-type: none"> <li>• Stelara</li> </ul>	<b>Specialty with PA</b> <ul style="list-style-type: none"> <li>• Stelara</li> <li>• Wezlana for Nuvaila (LW &amp; HW)</li> </ul>

## Down-tiers

Medications may move to a lower tier or be added to the formulary throughout the year, helping members take immediate advantage of cost savings.

Therapeutic use	Medication name	EHB Base	EHB Enhanced	Programs				Effective date
				SP	PA	ST	QL	
<b>Anti-Migraine Agents</b>	Nurtec ODT 75mg (Rimegepant)	2	2		X		X	10/1/24
<b>Hematological Agents</b>	Xolremdi (mavorixafor) capsule	4	5		X		X	10/1/24

---

## Up-tiers

Medications may move to a higher tier on Jan. 1.

*Please note there are no up-tiers at this time.*

---

## New brand launches and new strengths

New brand name medications and new strengths launch throughout the year. Final coverage status for new medications is determined after thorough review by the Optum Rx Pharmacy & Therapeutics Committee. New brand launches may include Authorized Brand Alternatives.\*

*Please note there are no new brand launches or strengths at this time.*

---

## New generic launches

New generic medication launches occur throughout the year.

*Please note there are no new generic launches at this time.*

---

PA

## Prior Authorization

Prior Authorization requires physicians to provide additional clinical information to verify member benefit coverage.

*Please note there are no additions or removals of this restriction at this time.*

---

ST

## Step Therapy

Step Therapy directs members to try a lower-cost alternative (Step 1) before a higher-cost medication (Step 2) may be eligible for coverage.

*Please note there are no additions or removals of this restriction at this time.*

---

## QL Quantity limits

Quantity limits establish the maximum quantity of a drug that is covered within a specified timeframe.

*Please note there are no additions or removals of this restriction at this time.*

---

## AR Age restrictions (this applies to a limited number of clinical programs)

*Please note there are no additions or removals of this restriction at this time.*



If you would like additional information that is not listed, please contact your Optum Rx representative.

At Optum, we help create a healthier world, one insight, one connection, one person at a time.

All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners.

© 2024 Optum, Inc. All rights reserved. OPT6773729\_EHBAugust2024

**Optum Rx**<sup>®</sup>